Table 3. Does chemotherapy affect supportive care (SC)?
| SC alone (n=90) | Vinorelbine (n=75) | Pa | |
|---|---|---|---|
| Drugs against treatment side effects | 41 (46%) | 35 (47%) | 0.89 |
| A01 Stomatologicals | 0 | 0 | |
| A02 Antacids | 29 (32%) | 14 (19%) | |
| A03 Antispasmodics | 4 (4%) | 5 (7%) | |
| A04 Antiemetics | 0 | 2 (3%) | |
| A06 Laxatives | 4 (4%) | 6 (8%) | |
| A07 Antidiarrhoeals | 1 (1%) | 1 (1%) | |
| B02 Antihaemorrhagics | 4 (4%) | 7 (9%) | |
| B03 Antianaemics | 1 (1%) | 3 (4%) | |
| J01 Antibacterials for systemic use | 10 (11%) | 6 (8%) | |
| J02 Antimycotics for systemic use | 0 | 1 (1%) | |
| L03AA Colony-stimulating factors | 0 | 5 (7%) | |
| Drugs against tumour symptoms | 66 (73%) | 53 (71%) | 0.70 |
| A14 Anabolic agents for systemic use | 3 (3%) | 3 (4%) | |
| A15 Appetite stimulants | 1 (1%) | 0 | |
| B01 Antithrombotic agents | 0 | 1 (1%) | |
| H01AA ACTH | 7 (8%) | 0 | |
| H02 Corticosteroids for systemic use | 45 (50%) | 32 (43%) | |
| L02AB Progestogens | 2 (2%) | 3 (4%) | |
| M01A Nonsteroidal anti-inflammatory drugs | 26 (29%) | 14 (19%) | |
| M05B Drugs affecting mineralisation | 5 (6%) | 1 (1%) | |
| N02A Opioids | 16 (18%) | 9 (12%) | |
| N02B Other analgesics and antipyretics | 12 (13%) | 8 (11%) | |
| N03 Antiepileptics | 0 | 0 | |
| R03 Antiasthmatics | 8 (9%) | 5 (7%) | |
| R05C Expettorants | 10 (11%) | 9 (12%) | |
| R05D Cough suppressants | 14 (16%) | 11 (15%) | |
| Drugs against concomitant diseases | 27 (30%) | 17 (23%) | 0.29 |
| A10 Antidiabetics | 1 (1%) | 0 | |
| C Cardiovascular system | 17 (19%) | 12 (16%) | |
| G04 Drugs for prostatic hypertrophy | 1 (1%) | 0 | |
| H03 Drugs for thyroid | 0 | 0 | |
| N05 Psycholeptics | 8 (9%) | 5 (7%) | |
| N06 Psychoanaleptics | 2 (2%) | 0 | |
| N07C Antivertigo preparations | 1 (1%) | 0 | |
Elderly patients randomised in the ELVIS trial. The table shows the number (percentage) of patients assuming at least one drug of each category during the first 63 days of treatment.
a
χ2 test.